This small-cap pharma stock has zoomed 2,166% in five years; check recent updates

Neuland Laboratories shares jumped nearly 20% to hit a high of ₹11,239.80 apiece during the fag-end of the session on Friday, August 2. 

The company reported its June quarter numbers on Thursday. Its PAT, or profit after tax, jumped 58% YoY to ₹98.3 crore from ₹62.2 crore logged in the year-ago period. On a sequential basis, the figure grew by 45.5%. 

Total income jumped 21.7% YoY to ₹444.4 crore, while EBITDA, or earnings before interest, taxes, depreciation, and amortisation, came in at ₹128.6 crore, up 29.5%. EBITDA margin jumped 174 basis points (bps) to 28.9%.

Basic earnings per share (EPS) came in at ₹76.6 from ₹48.5 in the corresponding quarter of the previous fiscal. 

Commenting on the performance, Sucheth Davuluri, Vice Chairman and Chief Executive Officer of the Company, said, “We recorded our highest ever quarterly revenues in Q1 FY25, led by growth in the CMS business, even as we recorded healthy EBITDA margins. We continue to maintain that FY25 will be a year of normalisation of revenue growth and, subsequently, margins as we continue to invest for growth. We expect our business to regain momentum from FY26 onwards based on our visibility from our portfolio of projects and products.”

The company is a part of the small-cap universe. 

Neuland Laboratories shares performance

The stock has been a multibagger. It has given 220% returns in the past 12 months and a whopping 2,166% returns in the past five years. In comparison, the Nifty Pharma index has given over 46% returns in one year and over 178% in five years.